50 results about "LIVER FATTY DEGENERATION" patented technology

The invention relates to a synergistic bifunctional protein for regulating blood sugar and lipid. The synergistic bifunctional protein comprises a human GLP-1 analog and human FGF21. In one aspect, the invention provides a method for preparing the synergistic bifunctional protein, and on the other hand, the invention also provides an application of the synergistic bifunctional protein for treatment of type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolism syndrome drugs. The synergistic bifunctional protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, and meet the multiple needs of hypoglycemia, alleviation of liver fatty degeneration, weight reduction and improvement of circulating lipid metabolism disorder in type 2 diabetic patients.

The invention discloses a composition with an auxiliary protection effect on an alcoholic liver injury and a preparation method of the composition. The composition with the auxiliary protective effect on the alcoholic liver injury is mainly prepared from the following raw materials in parts by weight: 57.5-172.5 parts of kudzuvine root extract, 22.5-67.5 parts of semen hoveniae extract, 35-105 parts of salvia miltiorrhiza extract, 18-57 parts of turmeric extract and 7.5-22.5 parts of ammonium glycyrrhetate. The raw materials respectively have anti-lipid peroxidation effect and protective effect on the liver. Functional tests show that the composition with the auxiliary protection effect on the alcoholic liver injury has better liver protection effect compared with the same dose of single kudzuvine root extract preparation and single semen hoveniae extract preparation, and liver fatty degeneration and liver lipid peroxidation which are caused by the alcoholic liver injury can be obviously alleviated. The composition with the auxiliary protection effect is prepared by adopting a scientific and reasonable production process, is definite in functions, controllable in quality and safe to take and is applicable to a large group of people suffering from the alcoholic liver injury.

The invention belongs to the field of traditional Chinese medicines and relates to a traditional Chinese compound medicament. The traditional Chinese compound medicament disclosed by the invention is prepared from atractylodes macrocephalaon polysaccharide, jasminoidin and chlorogenic acid in weight ratio of (100-500):(10-150):(1-50). The traditional Chinese compound medicament is produced into oral solid preparations such as granules, tablets and capsules by using a conventional method. Through a high fat die-induced rat fatty liver model experiment, screening applying uniform design and repeated verification, the results show that the traditional Chinese compound medicament has the efficacies that the content of triglyceride of a rat liver tissue in the model can be remarkably reduced, the liver fatty degeneration degree and liver damage are alleviated and no remarkable effect is achieved by a single component; and the compound medicament can be used for preparing medicaments for preventing and controlling simple fatty liver and fatty hepatitis or can be used for preparing medicaments for preventing and controlling the fatty liver diseases.

The invention discloses an application of a cholesterol ester synthase ACAT1 inhibitor in preparation of a medicine for preventing/treating non-alcoholic fatty liver disease, and belongs to the fieldof biomedicines. According to the invention, the cholesterol ester synthetase ACAT1 inhibitor-avasimibe is used for preventing/treating the non-alcoholic fatty liver disease, and in-vivo animal experiment results show that the avasimibe can reduce fat deposition in the liver of a high-fat animal model mouse and improve the fatty degeneration degree of the liver, so that the avasimibe has the effect of improving the non-alcoholic fatty liver disease. The avasimibe as the medicine and a medicine composition has a good application prospect in the aspect of preventing and treating the non-alcoholic fatty liver disease, and the development potential is very great.

The invention discloses Bifidobacterium pseudocatenatum and application thereof. The strain is separated from human intestinal tract for the first time, the sequence of 16S rRNA gene of the strain isshown as SEQ ID No.1, the strain is named DX1, and the preservation number is CCTCC NO: M 2019852. A mouse model proves that the DX1 strain has probiotic effects of relieving obesity, abnormal blood glucose homeostasis and liver steatosis; the DX1 strain can obviously reduce the weight, improve glucose tolerance and insulin resistance and improve liver steatosis in a high-fat diet mouse, does notcause systemic inflammation and intestinal inflammation, has certain safety, and lays a certain theoretical foundation for preventing or treating metabolic diseases such as obesity and diabetes.

The invention provides lactobacillus paracasei B111H and an application thereof to metabolic syndrome, and relates to the technical fields of microorganisms and an application thereof. The lactobacillus paracasei strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No: 22184. The preservation time is April 14, 2021. The lactobacillus paracasei is separated and screened from human excrement, has the effects of remarkably inhibiting liver cell lipid accumulation, reducing body weight and blood fat level and further improving liver fatty degeneration, and has important application significance in relieving hyperlipidemia, obesity and fatty liver. The discovery of the strain provides a new microbial resource for foods or drugs for reducing blood fat.

The invention relates to the technical field of medicines, and especially relates to application of Pyr3 in preparation of a medicine for protecting liver injury. Experiments prove that the pyr3 inhibit the level change of ALT, AST, HA, Collagen I and/or alpha-SMA, and can improve liver fibrosis, liver fatty degeneration, liver cell necrosis, inflammatory cell infiltration, connective tissue proliferation and/or hepatic lobule structural disorder, and compared with a control group, the Pyr3 has a remarkable protection effect on liver tissue. Therefore, the invention provides application of Pyr3 in preparation of a medicine for treating fibrosis, and further provides a liver injury protection medicine containing Pyr3.

The invention relates to application of puerarin in a V crystal form in preparing a drug for preventing, treating and/or alleviating hepatic pathological changes caused by diabetes mellitus, especially the hepatic steatosis, fibrosis and the hepatic pathological changes caused by the diabetes mellitus. The diabetes mellitus refers to the diabetes mellitus I and II. The drug is a clinical solid drug prepared from the puerarin in the V crystal form, other active ingredients and an excipient, wherein 1-1000 mg of the pueratin as an active ingredient is taken orally by one patient every day per kgof body weight.

The invention relates to a human leukocyte protease inhibitory factor as well as recombinant preparation and an application thereof, which belong to the field of biological medicines. The amino acid sequence contained in the human leukocyte protease inhibitory inhibitor is as follows: (1) an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; (2) an amino acid sequence obtained by connecting a label to the N end or/and C end of the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; and (3) an amino acid sequence which is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 or SEQ ID NO: 3 and has the activity of the human leukocyte protease inhibitory factor. The preparation method comprises the following steps: constructing plasmids, carrying out inducible expression to obtain fusion protein, purifying, and carrying out renaturation concentration. The protein provided by the invention has important application in preparation of drugs for treating metabolic diseases, and can reduce weight, inhibit increase of adipose tissue weight and inhibit liver fatty degeneration.

The invention discloses an application of apoptosis signal-regulating kinase 1 (ASK1) in screening drugs for preventing, relieving and/or treating steatohepatitis by taking N-terminal dimerization of ASK1 as a target. The invention further discloses a method for screening drugs for preventing, relieving and/or treating steatohepatitis by taking N-terminal dimerization of ASK1 as the target. The invention firstly discloses that the N-terminal dimerization of ASK1 has important significance on the phosphorylation activation of ASK1 and the signal path of ASK1-JNK, has an important regulation role in fatty degeneration of liver cells, and can promote the fatty degeneration development of the liver. By taking N-terminal dimerization of ASK1 as the target and detecting whether candidate substances inhibit the N-terminal dimerization of ASK1, novel drugs for preventing, relieving and/or treating steatohepatitis can be screened.

The invention discloses application of maca and moringa oleifera in treatment of alcoholic fatty liver disease, and belongs to the field of traditional Chinese medicine. The application proves that maca and moringa oleifera can intervene in the alcoholic fatty liver disease, can significantly reduce serum biochemical indexes such as ALT, TC and TG, and can improve liver fatty degeneration and lipid droplet reduction. The application expands a new direction for drug effect research of maca and moringa oleifera, and provides a new research drug for treatment and intervention of the alcoholic fatty liver disease.

The invention relates to application of a microbial metabolite in relieving glucose and lipid metabolism disorder, and particularly relates to application of AMP protein in preventing and/ or treatingobesity, fatty liver, diabetes and hyperlipidemia. By means of the application, the body weight gain and the blood fat content induced by high fat can be effectively reduced, the glucose tolerance isimproved, deposition of subcutaneous fat and visceral fat is reduced, liver damage and liver fatty degeneration are relieved, and the AMP protein has great significance in relieving obesity and fattyliver and is wide in application prospect.

The invention belongs to the field of pharmaceutical chemistry, and in particular relates to novel applications of pegylated curcumin derivative, especially the applications of the pegylated curcumin derivative in preparing medicines for preventing or treating fatty liver diseases and atherosclerosis. The experiment proves that the pegylated curcumin derivative can reduce the level of triglyceride in the blood, activate the phosphorylation of cyclic-AMP response element binding protein (CREB), negatively regulate nuclear transcription receptor PPAR gamma closely related to lipid metabolism, reduce the CD36 expression of the lever tissue caused by high fat diet, reduce the intake of fatty acid of the liver, reduce the lipid formation of the liver, and improve the fatty degeneration of the liver. The pegylated curcumin derivative further can improve the level of high density lipoprotein cholesterol, promote the reverse cholesterol transport, reduce the CD36 expression of macrophages, reduce the intake of oxidized low density lipoprotein, alleviate the bubblization of the macrophages, and reduce the deposition of lipid on the endangium and the formation of artery atherosclerotic plaque.

The invention provides a use of penthorum chinense pursh or an extract thereof in preparing health-care products or medicines for preventing or treating non-alcoholic fatty liver disease. Study indicates that the penthorum chinense pursh and the extract thereof have excellent prevention or treatment effect on the non-alcoholic fatty liver disease, and are capable of effectively reducing the ALT (Alanine Aminotransferase) level and the TBIL (Total Bilirubin) level in blood serum, reducing the TG (Triglyceride) level in the blood serum, increasing the HDL-C (High-Density Lipoproteincholesterol) level in the blood serum, reducing the TG and NEAF (Non-Esterified Fatty Acid) contents in the liver tissue, improving the GSH-PX (Glutathione Peroxidase) activity and relieving liver fatty degeneration, and therefore, a new option is provided for clinical medication for treating the non-alcoholic fatty liver disease.

The invention discloses application of short-chain fatty acid in prevention or/and treatment of liver injury. The short-chain fatty acid is a product of intestinal flora glycolysis dietary fibers, belongs to an endogenous substance, is small in toxic and side effects, simple in structure, easy to metabolize, convenient to obtain and low in price, and can inhibit liver fatty degeneration and liver inflammation, improve liver functions and prevent or/and treat liver injury.

The invention discloses application of chuanminshen violaceum or a chuanminshen violaceum extract to lipid regulation and atherosclerosis resistance. Research results show that the high-dose CEE has relatively high capacity of reducing serum TC and LDL-C, and has certain functions of increasing HDL-C and reducing TG. The CEE plays roles in regulating blood fat and protecting tissue lesions such asatherosclerosis and liver fatty degeneration by inhibiting lipid metabolism key enzymes such as ACAT and DGAT, and the related lesion process can be delayed.

The invention relates to a medicine for treating liver depression and spleen deficiency syndromes and in particular provides a pharmaceutical composition for treating liver depression and spleen deficiency syndromes as well as a preparation method and application thereof. The pharmaceutical composition for treating the liver depression and spleen deficiency syndromes contains the following components: astragalus, processed bighead atractylodes rhizome, raw coix seed, salviae miltiorrhizae, rhizoma cyperi, radix bupleuri, oriental wormwood, polygonum cuspidatum, concha arcae, verbena, semen cassiae, raw hawthorn and fructus polygoni orientalis. The pharmaceutical composition for treating liver depression and spleen deficiency syndromes has the following effects when applied to a patient suffering from non-alcoholic type fatty liver disease (NAFLD): clinical symptoms and signs of the NAFLD patient are obviously alleviated; liver function and blood lipid parameters of the patient can be safely and effectively reduced, and the effects of protecting the liver, lowering transaminase and lowering lipid are realized; and hepatic steatosis degree of the patient is obviously reduced.

The invention provides application of trilobatin in preparation of a medicine for preventing and/or treating non-alcoholic fatty liver disease. The trilobatin is researched and found for the first time to be capable of improving blood glucose metabolism disorder, abnormal blood lipid metabolism, liver function impairment, liver inflammatory response, liver injury, liver fatty degeneration and lipid deposition caused by the non-alcoholic fatty liver disease, and the trilobatin and the derivative thereof have a good treatment effect on the non-alcoholic fatty liver disease. The invention provides a novel and efficient natural medicine source for treating the non-alcoholic fatty liver disease.